Navigation Links
Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
Date:5/7/2011

number of attributes that may provide clinically important advantages over several comparator products:

  • Eight to 16 times more potent than azithromycin and is active against organisms that have become resistant to azithromycin
  • Potent in vitro activity against all important respiratory pathogens, including pneumococci, beta-hemolytic streptococci, staphylococci, Hemophilus, Legionella, Mycoplasma, Moraxella and Chlamydophila
  • Potent in vitro activity against other medically significant pathogens, including CA-MRSA, M. avium, malaria, enterococci and gonococci
  • Good tolerability to date as demonstrated in Phase 1 trials of the oral formulation
  • Low resistance frequency in vitro
  • No inhibition of the acetylcholine nicotinic receptor, unlike telithromycin; such inhibition is believed responsible for certain adverse effects observed with telithromycin (Ketek®).
  • Excellent tissue distribution and intracellular tissue concentrations, including lung epithelial lining fluid and alveolar macrophages
  • Oral and IV formulations concurrently in development
  • Once-daily dosing

Potential for indications beyond CABP, including urethritis and other urogenital infections, bioterrorism targets, malaria, M. avium infections and tuberculosis

About TAKSTA™

TAKSTA, (sodium fusidate) is a novel class of antibiotic with an established history of safety and efficacy outside the United States. TAKSTA is being developed as an NCE in the U.S. for ABSSSI. Clinical trials with TAKSTA employ a proprietary front-loading oral regimen designed to increase potency, increase coverage and minimize resistance development. Cempra believes that TAKSTA will be an important addition to anti-MRSA therapies based on the following:

  • Sodium fusidate is orally active against gr
    '/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
2. New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies
3. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
4. Reportlinker Adds Global Intravenous (IV) Iron Drugs Industry
5. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
6. Reportlinker Adds Intravenous Equipment - A World Market Intelligence Report
7. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
8. Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
9. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
10. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
11. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, ... and development agreements between biotech companies, military ... biotech solutions & therapies with regards to ... to positive clinical enhancements for regenerative medicine ... with recent developments, partnerships and advancements in ...
(Date:8/3/2015)... Biosensors International Group, Ltd. ("Biosensors" or ... B20), a developer, manufacturer and marketer of innovative ... first fiscal quarter ended 30 June 2015 ("Q1 ... Developments: , Biosensors continued to ... driven by lower operating expenses and operational improvement. ...
(Date:8/3/2015)... Colo., Aug. 3, 2015  Array BioPharma Inc. ... the fourth quarter and full year of its ... Ron Squarer, Chief Executive Officer of Array, noted, "Binimetinib ... 3, are on track for regulatory submissions in ... BRAF-mutant melanoma and BRAF-mutant colorectal cancer further validate ...
Breaking Medicine Technology:Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ( www.generex.com ... investor update conference call for late November.  The purpose ... update on (i) the status of the Company,s efforts ... wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ), ...
... 24, 2011 Neuralstem, Inc. (NYSE Amex: CUR ... trial of the company,s spinal cord stem cells in the ... at Emory University in Atlanta, Georgia. The company announced that, ... Food and Drug Administration (FDA) has granted approval for the ...
Cached Medicine Technology:Generex Announces Investor Update Conference Call Planned for Late November 2Generex Announces Investor Update Conference Call Planned for Late November 3Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial 2Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial 3Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial 4
(Date:8/4/2015)... ... August 04, 2015 , ... The goal of looking ... the desire for invasive surgery to achieve this ideal is not. But minimally invasive ... crave without the high cost or lengthy recovery time, according to Valerie Goldburt, ...
(Date:8/4/2015)... St. Louis, MO (PRWEB) , ... August 04, ... ... news, attorneys handling national talcum powder lawsuits filed against Johnson & Johnson report ... documents.* Talcum powder lawyers provide regular news updates and cancer warning ...
(Date:8/4/2015)... ... 2015 , ... Please join us for the 4th Annual Doris A. ... Shores Park in Brewerton, NY. , Doris Connor was a healthy, active, Registered ... age of 59. Her family and friends have since become steadfast in their efforts ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mr Didier Cauchois, ... impressive so far". , Mr Cauchois attributes the success to the dedication ... Dicma and the healthcare technology offered by Winscribe's platform. , "We have ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... partnership to make the Isabel Symptom Checker available to all users of the ... mechanism to check their symptoms in an easy, intuitive method, provides access to ...
Breaking Medicine News(10 mins):Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 2Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3
... Eastern Time Today -, IRVINE, Calif., March 13 ... in intravascular patient temperature,management therapies, today reported on its ... year ended December 31, 2007., Revenue for the ... to $2.0 million in the fourth quarter of 2006. ...
... In many areas of the modern world, molecules play ... Taxol is used to combat cancer, and aspirin is ... worldwide. MOLECULES THAT CHANGED THE WORLD (Wiley-Blackwell; March 2008; ... comprehensive guide to not only the synthesis of, but ...
... The following is a,statement by Lois Aronstein, AARP ... including a $400 million Housing,Opportunity Fund to improve the ... be used to provide needed opportunities,for low- and moderate-income ... The program will be administered by the State of ...
... to Expand Brand Awareness with the Strategic Placement, ... Event. Six Members of, this Year,s Field utilize ... RIDGE, N.J., March 13 Millennium,Biotechnologies Inc., wholly-owned ... MBTG) announced today that many PGA,players and spectators ...
... March 13 HHS, Agency for,Healthcare Research and ... health,information technology contracts that will focus on the ... clinical,decision support. Clinical decision support helps health professionals ... Women,s Hospital in Boston and Yale University School,of ...
... showed significant improvement in social functioning , , THURSDAY, ... 30 minutes of exercise a day can improve the ... American researchers suggest. , The analysis studied hundreds ... the Dose Response to Exercise in postmenopausal Women (DREW) ...
Cached Medicine News:Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 2Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 3Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 4Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 5Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 6Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 7Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 8Health News:Molecules that changed the world 2Health News:SURGEX(TM) Joins the Team of Sponsors for the PGA Tour's 2008 Arnold Palmer Invitational Presented by MasterCard 2Health News:SURGEX(TM) Joins the Team of Sponsors for the PGA Tour's 2008 Arnold Palmer Invitational Presented by MasterCard 3Health News:SURGEX(TM) Joins the Team of Sponsors for the PGA Tour's 2008 Arnold Palmer Invitational Presented by MasterCard 4Health News:AHRQ Awards $5 Million to Help Integrate Clinical Decision Support Technologies Into Health Care Delivery 2Health News:Minimal Exercise Benefits Overweight Postmenopausal Women 2
... manufactures two groups of flexible lighting products. ... non-sterile in three different sizes 5", 10", ... portion of the light). These lights are ... is needed., ,The second group of ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... Aaron manufactures two groups of flexible lighting ... and non-sterile in three different sizes 5", ... shaft portion of the light). These lights ... light is needed., ,The second group ...
Designed to be used for neuromuscular blockage monitoring. Provides for easy placement over the ulnar nerve on a patient's wrist. Dual element permits non-invasive monitoring using a single electrode...
Medicine Products: